Aethlon Medical Enters Into Materials Transfer Agreement for Santersus AG's NucleoCapture and HemoNucleoCapture Devices
- None.
- None.
Insights
The announcement by Aethlon Medical to conduct pre-clinical studies exploring potential synergies with Santersus AG's NucleoCapture devices represents a strategic move in the biotechnology and medical device sector. From a research perspective, the collaboration aims to leverage the Hemopurifier® system's ability to filter harmful exosomes and viruses in conjunction with NucleoCapture's removal of Neutrophil Extracellular Traps (NETs). NETs are implicated in various diseases, including cancer and autoimmune disorders and their removal could be critical in improving patient outcomes.
Combining these technologies could potentially enhance the efficacy of treatments such as immune checkpoint inhibitors or CAR T cell therapies, which are at the forefront of cancer treatment innovation. The pre-clinical studies will provide valuable data on the efficacy and safety of these combined approaches. If successful, this could lead to a new paradigm in the treatment of cancer and kidney transplantation, potentially improving survival rates and reducing complications associated with these conditions.
From an industry perspective, the partnership between Aethlon Medical and Santersus AG could signal an emerging trend of collaboration between companies to create multi-modal therapeutic devices. The medical device industry is highly competitive and innovations that offer a combination of treatment modalities can position a company favorably in the market. The focus on extracorporeal treatments aligns with a growing interest in less invasive procedures that can complement systemic therapies.
Should the pre-clinical studies yield positive results, the potential for commercialization and market penetration could be significant, especially in high-need areas like oncology and organ transplantation. It's important to monitor the progress of these studies as they could influence the strategic direction of both companies and impact their market value and investor sentiment.
From a financial standpoint, the Materials Transfer Agreement (MTA) between Aethlon Medical and Santersus AG is an early-stage investment in research and development that could have long-term financial implications. The success of the pre-clinical studies could lead to further collaboration, increased funding and eventual product development that meets a significant unmet medical need.
Investors should consider the R&D costs associated with such studies and the potential for delays or setbacks. However, the strategic partnership could also open up additional funding opportunities, such as grants or venture capital, particularly if the initial data is promising. The impact on Aethlon Medical's stock price will depend on the outcomes of the studies and the perceived market potential of the combined technologies.
Aethlon Medical Will Perform Pre-Clinical Studies to Explore Potential Synergies With its First-in-Class Hemopurifier® Blood Filtration System
Under the terms of the MTA, Santersus will supply Aethlon with NucleoCapture and HemoNucleoCapture devices, designed to remove Neutrophil Extracellular Traps (NETs), which are toxic to tissues and organs and are implicated in the pathophysiology of cancer, sepsis, autoimmune diseases, such as lupus, and ischemia reperfusion injury in organ transplantation.
Aethlon will perform initial pre-clinical studies to examine the NucleoCapture and HemoNucleoCapture devices, alone, and in combination with Aethlon's Hemopurifier® -- a therapeutic blood filtration system designed to bind and remove harmful exosomes and life-threatening viruses from blood and other biological fluids -- to assess their ability to remove important targets in samples from cancer patients, as well as from perfusates from kidneys that have undergone machine perfusion as part of the renal transplantation process.
"We look forward to initiating pre-clinical studies shortly, to expand upon the data that Santersus has generated in sepsis and liver and lung transplantation, and more importantly, to explore potential synergies with our Hemopurifier, initially in oncology and renal transplantation, as well as other potential indications," stated James Frakes, Interim Chief Executive Officer and Chief Financial Officer of Aethlon Medical. "Our belief is that the NETs removed by the NucleoCapture and HemoNucleoCapture devices, in combination with the clinical mediators removed by our Hemopurifier, could have an additive or synergistic effect in both the cancer and kidney transplant settings. The signing of the MTA represents an important milestone for both companies, as it is the first step toward a potential future collaboration."
"Our collaboration with Aethlon has provided us with research and development partners with expertise and capabilities to help advance our NucleoCapture technology platform forward in important fields, such as oncology and kidney transplantation. We are excited to continue building on the progress we've made in Santersus thus far and on taking the next steps forward in executing on our plans to advance NucleoCapture technology," commented Scott Maguire, Chairman of Santersus. "NETs are being increasingly recognized as an important element in cancer progression and metastasis. We believe extracorporeal removal of NETs using NucleoCapture either alone or in combination with Hemopurifier technology might create a transformational treatment option for patients receiving immune checkpoint inhibitors or CAR T cell therapies."
About Santersus AG
Santersus AG is a clinical stage privately held therapeutic apheresis Anglo-Swiss company. In clinical trials, Santersus' flagship medical device, NucleoCapture, has demonstrated the removal from patient blood of Neutrophil Extracellular Traps (NETs). NETs are fibers of decondensed DNA decorated with cytotoxic proteins that have been released from activated neutrophils. NETs have been recognized as one of the major driving factors in the development of sepsis, cancer, acute organ failure, autoimmune flares, and neurodegeneration, including Alzheimer's disease. NucleoCapture has been granted designation as a Breakthrough Device by the US Food & Drug Administration (FDA). NucleoCapture blood purification technology is based on biocompatible, highly porous polymer beads conjugated with proprietary human recombinant histone H1.3 protein. Histone H1.3 protein was created in nature to act as the ultimate human DNA binding and compacting protein with single digit nanomolar DNA binding constants. As a result, in clinical trials Santersus has demonstrated that a single pass of NETs contaminated blood through the NucleoCapture device results in over
Additional information can be found at www.Santersus.com
About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful exosomes from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a
Additional information can be found at www.AethlonMedical.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Aethlon's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences include, without limitation, the Company's ability to successfully raise additional capital and to complete development of the Hemopurifier and to successfully demonstrate the utility of the Hemopurifier in cancer and infectious diseases; the Company's ability to demonstrate synergies of the Hemopurifier with the NucleoCapture and HemoNucleoCapture devices; the Company's ability to enter into a future collaboration with Santersus; the Company's ability to complete the internal binding study of relevant extracellular vesicles; the Company's ability to commence and manage its clinical trials; and other potential risks. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2023, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Interim Chief Executive Officer and Chief Financial Officer
Aethlon Medical, Inc.
Jfrakes@aethlonmedical.com
Investor Contact:
Susan Noonan
S.A. Noonan Communications, LLC
susan@sanoonan.com
917-513-5303
View original content:https://www.prnewswire.com/news-releases/aethlon-medical-enters-into-materials-transfer-agreement-for-santersus-ags-nucleocapture-and-hemonucleocapture-devices-302067186.html
SOURCE Aethlon Medical, Inc.
FAQ
What is Aethlon Medical exploring with Santersus AG in pre-clinical studies?
What are Neutrophil Extracellular Traps (NETs) and their implications?
Who is the Interim CEO and CFO of Aethlon Medical?
What is the potential collaboration milestone achieved between Aethlon Medical and Santersus AG?
What treatment options do Aethlon and Santersus aim to create?
